LITT for Ultra-early GBM Recurrence
Recruiting
N/A
Interventional Study
Glioblastoma (GBM)
Glioblastoma - Category
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 12 (estimated)
- Sponsor
- Insel Gruppe AG, University Hospital Bern · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.
LITT offers a minimally invasive alternative that may:
* Tre…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
* ≥18 years of age
* CRET
* Karnofsky Performance Status (KPS) ≥70
* No contra-indication for radio-chemotherapy
* Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
* Able to …
Contacts